Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$236.34 USD
-5.84 (-2.41%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $236.50 +0.16 (0.07%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.34 USD
-5.84 (-2.41%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $236.50 +0.16 (0.07%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Three Reasons to Retain BD (BDX) Stock in Your Portfolio Now
by Zacks Equity Research
BD's (BDX) robust product portfolio raises optimism about the stock.
BD's (BDX) FDA-Approved Test to Offer Wider Testing Access
by Zacks Equity Research
BD's (BDX) receipt of the FDA's clearance for the use of self-collected vaginal specimens for HPV testing is likely to improve screening access to a wider female population.
Stock Market News for May 3, 2024
by Zacks Equity Research
U.S. stock markets closed sharply higher on Thursday.
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Compared to Estimates, Becton Dickinson (BDX) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Becton Dickinson (BDX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
BD (BDX) Q2 Earnings Surpass Estimates, FY24 View Revised
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in all segments and both geographic regions in the fiscal second quarter.
Becton Dickinson (BDX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 7.09% and 0.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for These 5 Medical Device Stocks in Q1 Earnings?
by Zacks Equity Research
Here is a sneak peek into how five medical device stocks, BDX, BAX, XRAY, CAH and DVA, might fare in their quarterly results slated to be released tomorrow.
Here's Why You Should Hold Lantheus (LNTH) in Your Portfolio Now
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
GE HealthCare (GEHC) Q1 Earnings In Line, Sales Volume Decline
by Zacks Equity Research
GE HealthCare's (GEHC) first-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.
Sustained Product Demand Likely to Aid BD's (BDX) Q2 Earnings
by Zacks Equity Research
Continued solid uptake of BD's (BDX) products is expected to have driven fiscal second-quarter revenues.
Revvity (RVTY) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Revvity's (RVTY) first-quarter results showcase a decline in life sciences segmental revenues. However, the company's earnings and revenues beat their respective estimates.
Bruker's (BRKR) Balanced Segmental Growth, Innovation Aid
by Zacks Equity Research
Bruker (BRKR) revenues continue to be driven by the strength of end markets, including academic, government and industrial.
Unveiling Becton Dickinson (BDX) Q2 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Becton Dickinson (BDX) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Philips (PHG) Receives FDA Warning Letter Regarding CT Systems
by Zacks Equity Research
Philips (PHG) receives a warning letter from the FDA in respect of a manufacturing plant in China regarding faults in the manufacturing of CT systems.
DexCom (DXCM) Q1 Earnings Beat, Strong CGM Demand Continues
by Zacks Equity Research
DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Revvity's (RVTY) New Launch to Boost Tuberculosis Testing
by Zacks Equity Research
Revvity's (RVTY) latest offering is likely to provide a new and improved workflow to lower hands-on time and enable increased lab productivity.
CONMED (CNMD) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
CONMED's (CNMD) adjusted first-quarter earnings and revenues beat estimates on the back of strong U.S. and International markets as well as supply-chain improvement.
Veeva's (VEEV) AI Partner Program to Develop GenAI Solutions
by Zacks Equity Research
Veeva (VEEV) announces the Veeva AI Partner Program, which is expected to provide partners assistance to combine Generative AI solutions with Veeva Vault applications.
West Pharmaceutical (WST) Q1 Earnings Beat, HVP Sales Weak
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.
Penumbra's (PEN) New Launch to Enhance Blood Clot Removal
by Zacks Equity Research
Penumbra's (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.
Reasons Why You Should Retain HealthEquity (HQY) Stock for Now
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
GE HealthCare's (GEHC) New Tie-Up to Boost Patient Outcomes
by Zacks Equity Research
GE HealthCare's (GEHC) latest partnership is likely to benefit global healthcare systems by enhancing Elekta's RT offerings with its MIM Software medical imaging management solutions.
Top 5 U.S. Giants at Lucrative Valuations Amid April Turmoil
by Nalak Das
We have narrowed our search to five U.S. bigwigs (market capital > $70 billion) with attractive valuations. These are: NVDA, MU, BDX, ANET, EQIX.
BDX or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BDX vs. MMSI: Which Stock Is the Better Value Option?